Standard Leadership, Compliance Assurance, and Technology Implementation: The 4th China Digital Therapeutics Product Quality and Regulatory Symposium Kicks Off in Shanghai on December 11 — Registration Now Open!
In 2025, the global healthcare industry is entering a phase of deep digital transformation. With the iterative maturation of technologies such as large AI models, brain-computer interfaces, and medical big data, digital therapeutics have expanded from single-disease intervention scenarios to multiple verticals, including chronic disease management, mental health, and pain treatment. They have become a core lever for addressing critical industry challenges such as population aging, uneven distribution of medical resources, and the mounting pressure of chronic disease prevention and control.
Amid the deepening policy implementation of the “Healthy China 2030” strategy, China’s digital therapeutics industry is ushering in opportunities for scaled development, while simultaneously confronting multiple challenges, including poor alignment with global standards, divergent cross-border regulatory policies, bottlenecks in technological translation and deployment, and ambiguous pathways for data valorization. To promote standardized and innovative industry development, facilitate in-depth dialogue among Chinese and foreign experts, regulatory authorities, and enterprises, and support companies in substantively participating in the formulation of industry standards,Hosted by the Digital Therapeutics Professional Committee of the China Medical Device Industry Association, organized by Chongqing Artery Orange Technology Co., Ltd., and jointly supported by Shanghai Tephon Intelligent Technology Co., Ltd., ResMed (Beijing) Trading Co., Ltd., Abbott Trading (Shanghai) Co., Ltd., and Lianren Health Medical Big Data Technology Co., Ltd., scheduled forDecember 11, 2025Held in ShanghaiThe 4th China Digital Therapeutics Product Quality and Regulatory SymposiumCentered on quality compliance, exploration of technical pathways, and the joint establishment of industry standards, this conference built a platform for exchange across the industrial chain, pooled industry expertise to address development challenges, and injected strong momentum into the high-quality upgrading of the digital therapeutics industry.
(Limited seats available, scan the QR code to register for free)
This seminar closely aligns with the industry development trends and core themes of 2025, focusing on key issues such as industrial environment trends, cross-border regulatory compliance, applications of cutting-edge technologies, and data value conversion. It provides industry peers with forward-looking and practical insights, helping enterprises identify their development direction amidst opportunities and challenges.
In-depth analysis of mainstream international regulatory frameworks and core cross-border compliance requirements, coupled with an assessment of annual development trends and industrial landscape transformations in frontier fields such as medical AI. From macro policy directions to pain points in industrial practice, this report comprehensively dissects the opportunities and challenges facing the industry, providing forward-looking guidance and practical references for corporate strategic planning and compliant operations.
Focusing on the core themes of compliant management, mining and analysis, and value conversion of medical health data, this discussion explores the key enabling role of data in the research and development of digital therapeutics products, optimization of clinical efficacy, and upgrading of service models. It analyzes the balanced pathway between data security and value release, shares the underlying logic of industry innovation driven by data, and provides systematic insights for the industry to break through data application bottlenecks and unlock the potential of data assets.
Focusing on the innovative integration of cutting-edge technologies, such as brain-computer interfaces and large language models, into the field of digital therapeutics, this initiative showcases new pathways for implementation and service loop construction in vertical scenarios like pain management and mental health. Leveraging the platform advantages of industry associations, it coordinates multi-stakeholder efforts—including regulatory bodies, research institutions, and industry players—to promote technology adoption and synergistic industrial development through resource matching, ecosystem expansion, and experience sharing, thereby consolidating collective innovation within the sector.
Innovation is the driving force, and standards provide the direction. As the industry’s premier annual event, the 4th China Digital Therapeutics Product Quality and Regulatory Symposium will establish an efficient platform for exchange among corporate leaders, technical experts, regulatory professionals, and academic researchers in the field of digital therapeutics. On December 11, join us in Shanghai to explore compliance pathways, discuss technological innovation, and shape industry standards, working together to propel China’s digital therapeutics industry into a new phase of standardized, high-quality development!
(Limited seats available; scan the QR code to register for free)